NeoGenomics, Inc. (NASDAQ: NEO) has expanded its partnership with Indica Labs to scale its digital pathology infrastructure using AI-driven diagnostic tools, according to a press release from the Fort Myers, Florida-based company.

NeoGenomics selected the Indica Labs HALO AP® platform to underpin its digital pathology operations through a cloud-based framework. The vendor-neutral image management system is designed to allow NeoGenomics to incorporate third-party or internally developed AI tools while limiting integration costs. The platform is intended to give customers access to digital pathology capabilities without requiring significant capital investment or complex IT integration.

The two companies have had a technology relationship since 2015. NeoGenomics said the expanded infrastructure is expected to support future AI co-development projects and clinical trial collaborations, as well as the growth of its curated pathology datasets.

"By scaling our digital pathology infrastructure with Indica Labs, we will have the ability to provide our pathologists and clinicians with more consistent, efficient workflows, while building the foundation we need to keep pace as AI becomes a core capability in cancer diagnosis and therapy selection," said Warren Stone, President and Chief Operating Officer of NeoGenomics.

Steven Hashagen, CEO of Indica Labs, said the partnership is intended to bring diagnostic innovations into clinical practice and support AI and clinical trial collaborations.

Dr. Beth Palla, Head of Breast Pathology at Scripps Clinic Medical Group, said NeoGenomics has been a partner in its digital pathology operations and that the expanded capabilities are expected to affect daily clinical practice.

NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories across the United States, as well as a laboratory in Cambridge, England. HALO AP® is CE-IVDR marked for diagnostic use in Europe, the United Kingdom, and Switzerland, and is designated for research use only in the United States, where it has not received FDA clearance for clinical diagnostic use.